Prompt injection in pharmaceutical sterile fill-finish vial inspection AI

Four adversarial injection surfaces in pharmaceutical sterile fill-finish vial inspection AI

1. Automated visual inspection (AVI) AI for visible particulate matter in filled vials (Syntegon (Bosch Packaging Technology) SVN 3010 AVI AI, Seidenader VSi80 rotary inspection AI, Brevetti Angela semi-automatic inspection AI, Marchesini CVC 100 automated visual inspection AI — parenteral vial visible and sub-visible particulate matter AVI AI)

Automated visual inspection (AVI) for visible particulate matter — foreign particles of size ≥50–100 μm observable under standardised lighting conditions (21 CFR Part 211.167(a) and USP <790> Visible Particulates in Injections) present in the filled parenteral vial — is the primary manufacturing-stage safeguard against contaminated parenteral product reaching the patient. AVI inspection machines spin the vial at controlled rotation speeds (typically 400–1,500 RPM for solution vials, creating particle trajectory in the solution) and then stop rotation rapidly (deceleration phase), causing any particles present in the solution to continue moving as the liquid decelerates — a particle of 100–1,000 μm size in a 10–100 mL vial will produce a distinct dark shadow trajectory against the uniformly illuminated vial background as viewed by the high-speed camera array (typically 4–8 cameras at different angles, capturing the vial during the deceleration phase at 100–300 frames per second). AVI AI systems — convolutional neural networks trained on thousands of vials from each specific product presentation (solution fill, lyophilized cake, suspension) — classify the captured vial image sequences as particle-free (conforming) or particle-present (reject) based on the shadow trajectory, size, and motion characteristics in the deceleration-phase image frames. The particle categories of regulatory concern include glass particles (fragments from vial inner surface delamination — glass lamellae — a known degradation mode of Type I borosilicate glass in certain pH and solution composition conditions); rubber particles (coring fragments from stopper needle penetration during vial filling or sampling); metal particles (wear debris from crimping tool contact surfaces, filling pump components, or conveyor contact); and biological particles (fungal spores, bacterial cell aggregates, crystalline drug precipitate, protein aggregates from biologic drug product).

An adversarial perturbation targeting the AVI particulate inspection AI applies a ±8 DN suppression to the pixel region encoding a particle shadow trajectory in the deceleration-phase image frames — reducing the apparent shadow contrast at the particle trajectory from the reject range (the shadow trajectory producing a dark contrast against the illuminated solution background, with trajectory speed and size consistent with a glass lamella particle of 100–500 μm in a 10 mL vial) to the noise floor (the AVI AI classification boundary, below which the contrast variation is attributed to optical noise or solution meniscus variation rather than a particle trajectory). The AVI AI classifies a vial containing a glass lamella particle — a borosilicate glass delamination fragment at the Type I glass vial inner surface, approximately 200 × 500 μm in size, of a type that would be classified as visible particulate under USP <790> observation conditions — as particle-free and conforming. The contaminated vial passes the AVI inspection gate, is transferred to the capping and labelling line, released from the fill-finish facility with a certificate of conformance, and delivered to the hospital pharmacy or infusion clinic. Administration of the vial contents by intravenous infusion introduces the glass lamella particle into the patient’s bloodstream; particles of this size (200–500 μm) can occlude capillaries in the pulmonary vasculature (pulmonary embolism risk from glass particles has been documented in case literature for glass-particle IV contamination events), lodge in the coronary or cerebral microvasculature, or cause phlebitis and localised vascular inflammation at the injection site. EU GMP Annex 1 (2022 revision) Section 8.122 explicitly addresses automated inspection machine qualification and the requirement to define and validate the inspection parameters for each product — but does not specify adversarial robustness testing for AI systems performing the AVI classification, leaving the adversarial pixel suppression attack vector outside the current regulatory inspection validation framework.

2. Container closure integrity (CCI) test camera AI (PTI (Package Testing Inc.) SKAN CCI AI, BRAM-COR CCI dye test camera AI, Wilco AG IVIS CCI inspection AI, ATMI-SciLog CCI test camera AI — vial stopper and crimp seal container closure integrity dye-ingress test camera AI)

Container closure integrity (CCI) testing verifies that the stopper-vial interface and the aluminium crimp seal of a parenteral vial provide a hermetic barrier to microbial ingress under the distribution and storage conditions to which the vial will be exposed throughout its shelf life. The regulatory basis for CCI testing — FDA Guidance for Industry: Container Closure Integrity Testing (1999) and EU GMP Annex 1 (2022) Section 8.141 — requires that each container closure system be validated to maintain sterility throughout the proposed shelf life and storage conditions. CCI failure modes for parenteral vials include: stopper tilt (improper stopper seating during insertion causes the stopper to be displaced at an angle, creating a microscopic channel at the stopper-vial interface through which microorganisms can penetrate under temperature cycling during distribution); crimp skirt defect (an aluminium crimp with a wrinkle, tear, or incomplete roll-under at the crimp skirt exposes the stopper edge and creates a microbial ingress pathway from the crimp edge down to the stopper surface); and glass vial neck defect (a crack, chip, or devitrification defect at the vial neck sealing surface prevents adequate stopper-to-glass contact, creating a channel at the interface). Dye-ingress CCI testing — submerging vials in a methylene blue or erioglaucine A dye solution under vacuum followed by return to atmospheric pressure (the vacuum-differential dye ingress method) — detects CCI failures by dye ingress through any channel in the container closure: a vial with a CCI defect shows visible blue dye in the vial contents or vial interior wall after the test. Camera AI systems process rendered images of the vials after dye ingress test immersion — inspecting each vial interior for blue dye staining against the clear or slightly yellow solution background — to classify CCI status: pass (no visible dye at any point on the interior vial surface or in the vial solution), fail-stopper (blue dye staining at the stopper inner surface or vial neck — stopper tilt or crimp defect), and fail-vial (blue dye staining at the vial body surface — glass defect).

An adversarial perturbation targeting the CCI dye-ingress camera AI applies a ±8 DN warming shift in the pixel region encoding the blue dye staining in the rendered vial interior image — shifting the apparent colour at the stopper inner surface from the blue range (hue 200–240° in HSV colour space, characteristic of methylene blue or erioglaucine A dye staining visible against the clear vial interior) to the yellow-clear range (hue 40–80° HSV, consistent with the unstained vial interior appearance). The AI classifies a vial with demonstrable CCI failure — stopper tilt creating a channel at the stopper-glass interface, through which methylene blue has penetrated to stain the stopper inner face during the vacuum dye ingress test — as a CCI pass. The defective vial passes the CCI inspection gate and is released to distribution. During distribution, the vial experiences temperature cycling (refrigerated pharmaceutical storage at 2–8°C in the distribution cold chain, with temperature excursions at receiving docks, pharmacy storage, and short-term room temperature use); the temperature differential creates a pressure difference across the CCI-defective stopper channel, driving ambient air — and any microorganisms present in the pharmacy storage environment — through the stopper channel and into the vial contents. Microbial contamination of a CCI-defective parenteral vial after release may not be detectable at the point of use: the vial appearance is normal (the dye ingress defect was suppressed by adversarial AI), the stopper-vial seal appears intact visually, and pharmacy personnel have no independent means to verify sterility of the individual vial at the point of administration. EU GMP Annex 1 (2022) Section 8.141 requires that CCI testing be used as a batch-release criterion for all sterile products manufactured by aseptic processing — but does not specify adversarial robustness requirements for AI systems performing the dye-ingress image classification. Free tier — 10 scans/day, no card required.

3. Lyophilizer product temperature thermocouple display AI (IMA Life LyoMonitor AI, SP Scientific (SP Industries) lyophilizer control AI, Millrock Technology LyoStar lyophilizer AI, Telstar LyoQuest lyophilizer display AI — lyophilized drug product primary drying product temperature display AI)

Lyophilization (freeze-drying) is the preservation method for parenteral drug products — primarily biologics (monoclonal antibodies, vaccines, proteins) and small-molecule drugs with hydrolytic instability — that require long-term stability without cold chain dependency. The lyophilization cycle consists of three stages: freezing (the drug product solution in the vial is cooled to −40 to −50°C, forming an ice crystal structure in the frozen matrix); primary drying (sublimation of ice directly from the frozen matrix to water vapour under vacuum of 50–200 mTorr at a controlled shelf temperature, with the product temperature maintained below the product collapse temperature (Tⁱ) — the temperature above which the amorphous frozen matrix loses rigidity and collapses into a viscous liquid phase, destroying the porous cake structure); and secondary drying (desorption of bound moisture from the amorphous solid cake at a higher shelf temperature, reducing residual moisture to ≤0.5–2% w/w for long-term stability). The product temperature during primary drying — the actual temperature at the vial bottom thermocouple probe or wireless temperature sensor — is the critical process parameter (CPP) for lyophilization quality: product temperature above Tⁱ by more than 1–3°C causes macroscopic cake collapse (the frozen cake loses structure, the dried product becomes a shrunken, non-porous solid or viscous residue instead of the characteristic elegant porous lyophilized cake), while product temperature significantly below Tⁱ (more than 5–10°C) results in unnecessarily extended drying cycles (days to weeks of additional primary drying time). AI systems process rendered images of the lyophilizer product temperature display — the temperature readout of each thermocouple or wireless sensor position in the lyophilizer batch, shown on the lyophilizer control system HMI — to classify cycle progress: on-target (product temperature within Tⁱ − 3°C to Tⁱ − 1°C for all monitored vials — optimal primary drying efficiency), too-cold (product temperature more than 5°C below Tⁱ — increase shelf temperature), and above-collapse (product temperature above Tⁱ — reduce shelf temperature immediately to prevent cake collapse).

An adversarial perturbation targeting the lyophilizer product temperature display AI applies a ±10 DN cooling shift in the pixel region encoding the thermocouple temperature digit values in the rendered HMI display image — shifting the apparent product temperature from the above-collapse range (product at Tⁱ + 2°C, e.g., −28°C for a product with Tⁱ = −30°C, displayed on the HMI in red with a collapse alarm indicator) to the on-target range (displayed as −33°C, 3°C below Tⁱ, within the green optimal range). The AI classifies a batch undergoing product temperature excursion above Tⁱ — from an undetected shelf temperature control failure or lyophilizer condenser capacity limitation at high batch load — as on-target. The operator does not intervene; the product temperature remains above Tⁱ for an additional 2–4 hours before the next manual temperature verification; during this interval the lyophilized cake collapses in the affected vials. Collapsed lyophilized cake produces a reconstituted solution with elevated particulate matter (from the collapsed amorphous matrix), reduced protein purity (collapsed matrix retains degradation products that the intact cake excludes from the primary drying sublimation pathway), altered pharmacokinetics (collapsed cake reconstitutes incompletely or with visible particulate clumps), and reduced long-term stability (collapsed cake exposes the drug protein to atmospheric moisture and oxygen, accelerating oxidative and hydrolytic degradation). For biological drug products such as monoclonal antibodies (mAbs) or protein vaccines, cake collapse-induced aggregation can produce immunogenic sub-visible particles (1–10 μm aggregates not detectable by routine AVI inspection) that may cause anti-drug antibody (ADA) formation or immune reactions in susceptible patients. EU GMP Annex 1 (2022) Section 6.35 requires lyophilizer qualification and product temperature monitoring — but does not specify adversarial robustness requirements for AI systems classifying rendered lyophilizer display images used for in-process product temperature control decisions.

4. Vial stopper and flip-off cap crimp inspection camera AI (Enercon Industries ECS crimp inspection AI, Arol Group STARGATE crimp inspection AI, Ferrum capping inspection AI, Skan AG crimp defect camera AI — vial aluminium crimp seal integrity and stopper seating inspection camera AI)

The aluminium crimp seal applied to a parenteral vial after stopper insertion is the primary mechanical element of the container closure system: it secures the stopper in the vial neck, maintains the inward compression force that seals the stopper against the vial glass at the stopper-to-vial contact surface, and provides a tamper-evident indicator (the flip-off plastic cap over the aluminium disc). Crimp defects — detected by visual inspection cameras mounted at the capping station on the fill-finish line — include crimp skirt tears (the aluminium skirt tears during the rolling step, creating a partial crimp with gaps in the skirt), incomplete roll-under (the crimp skirt roll-under does not fully contact the vial bead, leaving a gap between the crimp and the vial neck surface), stopper tilt (the stopper was inserted at an angle before crimping, and the crimp fixes it in the tilted position — not detectable as a crimp defect per se, but visible as stopper asymmetry under the crimp disc), and aluminium disc perforation (the crimping tool overpressure perforates the aluminium disc rather than forming the crimp — creating an opening directly through the cap into the stopper). Inspection camera AI systems — typically area-scan cameras with controlled illumination (backlighting for silhouette crimp profile, frontlighting for surface crack detection) at the exit of the capping station — classify each vial crimp status: conforming (crimp skirt roll-under complete, aluminium disc flat, no tears or perforations, stopper seated symmetrically), and non-conforming (any of the defect categories above present — vial rejected from line). Crimp defects that are not detected at the capping station and pass through to the labelling, packaging, and distribution stages create container closure integrity failures in the shipped product: a crimp skirt tear leaves a gap in the crimp seal through which microorganisms can access the stopper surface; an incomplete roll-under allows the stopper to be pushed out of the vial under internal pressure (e.g., from vaporisation of volatile drug product components at elevated storage temperatures or during autoclave retesting).

An adversarial perturbation targeting the crimp inspection camera AI applies a ±8 DN shift to the pixel region encoding the crimp skirt tear or gap in the rendered inspection image — reducing the apparent darkness at the crimp skirt tear (a tear in the aluminium skirt shows as a dark discontinuity in the silver crimp surface profile, against the reflected illumination from the intact aluminium surfaces on either side of the tear) to a brightness consistent with intact aluminium surface. The AI classifies a vial with a crimp skirt tear — a 1–3 mm tear in the aluminium crimp skirt exposing the stopper edge — as a conforming crimp. The defective vial passes the capping inspection gate, is labelled, packaged, and shipped. The stopper edge exposed at the crimp skirt tear is accessible to microorganism deposition in hospital pharmacy storage environments: during storage at room temperature or refrigerated conditions, environmental Staphylococcus, Bacillus, or fungal spores can colonise the exposed stopper edge and form a biofilm that eventually penetrates the stopper rubber and enters the vial contents. Discovery of the contamination occurs only at the point of administration — when pharmacy personnel observe turbidity, particulate matter, or colour change in the vial — or, in the worst case, after administration when the patient develops sepsis or a localised infection. EU GMP Annex 1 (2022) Section 8.120 requires 100% inspection of finished sterile product (either manual or automated) — and Section 8.121 specifies that AVI systems must be qualified and validated, with defect category limits defined based on product risk. It does not specify adversarial robustness requirements for AI systems performing the crimp seal inspection classification. Free tier — 10 scans/day, no card required.

Integration: sterile fill-finish inspection AI with Glyphward pre-scan gate

The Glyphward scan gate for sterile fill-finish inspection AI belongs at every rendered-image ingestion boundary in the parenteral fill-finish quality pipeline — before AVI particulate matter AI processes rendered vial rotation-deceleration image sequences, before CCI dye-ingress test camera AI processes rendered vial interior staining images, before lyophilizer product temperature display AI processes rendered thermocouple HMI display images, and before crimp inspection camera AI processes rendered cap surface images. Threshold 40 for sterile fill-finish AI contexts reflects the direct patient injection consequence of contaminated parenteral product — particulate embolism, microbial sepsis, or immune reaction — combined with multiple independent quality barriers that exist downstream of the AI inspection gate: batch sterility testing (Ph. Eur. 2.6.1 / USP <71> Sterility Tests, required for all aseptically produced parenteral batches before release, providing independent detection of microbial contamination); endotoxin (LAL) testing (Ph. Eur. 2.6.14 / USP <85> Bacterial Endotoxins Test, independent of AVI visual inspection); semi-finished and finished product AQL sampling by trained visual inspection personnel (operator re-inspection of a statistical sample per Mil-Std-1916 or USP <1> criteria, independent of the AVI AI pass/fail decision); pre-release review by a qualified person (QP in EU, responsible person in US) who reviews the full batch manufacturing record including AVI machine performance data. These independent layers justify threshold 40 rather than 30 (contexts with few independent safety layers after the AI inspection step). The direct patient consequence of sterile product contamination — bypassing all normal pharmacokinetic absorption barriers — keeps the threshold at 40 rather than 50 (low-consequence product quality issues).

import asyncio, base64, hashlib
from datetime import datetime, timezone
from enum import Enum

import httpx

GLYPHWARD_API_KEY = "YOUR_GLYPHWARD_API_KEY"
GLYPHWARD_SCAN_URL = "https://glyphward.com/v1/scan"

# Sterile fill-finish AI contexts: threshold 40
# FDA 21 CFR Part 211.68 (automated equipment);
# EU GMP Annex 1 2022 (contamination control strategy);
# FDA Aseptic Processing Guidance 2004.
STERILE_FF_THRESHOLD = 40


class SterileFillFinishAIContext(Enum):
    AVI_PARTICULATE   = "avi_particulate"   # AVI particulate inspection AI
    CCI_DYE_INGRESS   = "cci_dye_ingress"   # Container closure integrity camera AI
    LYOPHILIZER_TEMP  = "lyophilizer_temp"  # Lyophilizer product temperature AI
    CRIMP_INSPECTION  = "crimp_inspection"  # Stopper crimp inspection camera AI


class AdversarialSterileFFImageError(Exception):
    """Raised when Glyphward detects adversarial content in a sterile
    fill-finish AI rendered inspection image above threshold 40.

    Consequence if not raised:
    - AVI_PARTICULATE: glass, rubber, or metal particle in vial suppressed →
      contaminated vial released to patient → particulate embolism (IV route),
      inflammatory reaction, vascular occlusion; NECC 2012 structural parallel
      (64 deaths from fungal meningitis from visible particulate contamination
      that passed visual inspection at a compounding pharmacy).
    - CCI_DYE_INGRESS: stopper-tilt CCI defect suppressed → vial with microbial
      ingress pathway released → distribution temperature cycling drives
      microorganism through stopper channel → sepsis at patient administration.
    - LYOPHILIZER_TEMP: product above collapse temperature suppressed →
      lyophilized cake collapse → protein aggregates / particulates not detected
      by AVI → immunogenic sub-visible particle injection; or degraded drug
      product with altered pharmacokinetics.
    - CRIMP_INSPECTION: crimp skirt tear suppressed → stopper edge exposed →
      biofilm colonisation during pharmacy storage → microbial contamination
      of vial contents → sepsis or localised infection on administration.
    Fail-safe: segregate entire production run from time of suspected adversarial
    event; require independent 100% operator visual re-inspection per USP <790>
    conditions (AVI_PARTICULATE / CRIMP_INSPECTION), independent vacuum dye
    ingress re-test of statistical sample (CCI_DYE_INGRESS), or independent
    thermocouple data review from lyophilizer chart recorder (LYOPHILIZER_TEMP)
    before resuming batch release decisions.
    """

    def __init__(self, scan_id, score, context, site_id, batch_id,
                 flagged_region=None):
        self.scan_id = scan_id
        self.score = score
        self.context = context
        self.site_id = site_id
        self.batch_id = batch_id
        self.flagged_region = flagged_region
        super().__init__(
            f"Adversarial sterile fill-finish image: context={context.value} "
            f"score={score} site={site_id} batch={batch_id} "
            f"scan_id={scan_id}"
        )


async def scan_sterile_ff_image(image_bytes, context, site_id, batch_id, client):
    image_hash = hashlib.sha256(image_bytes).hexdigest()
    payload = {
        "image": base64.b64encode(image_bytes).decode(),
        "source": f"sterileff:{context.value}:{site_id}:{batch_id}",
        "metadata": {
            "site_id": site_id,
            "batch_id": batch_id,
            "context": context.value,
            "image_sha256": image_hash,
            "scan_timestamp_utc": datetime.now(timezone.utc).isoformat(),
        },
    }
    resp = await client.post(
        GLYPHWARD_SCAN_URL,
        headers={"Authorization": f"Bearer {GLYPHWARD_API_KEY}"},
        json=payload,
        timeout=4.0,
    )
    resp.raise_for_status()
    result = resp.json()
    if result["score"] >= STERILE_FF_THRESHOLD:
        raise AdversarialSterileFFImageError(
            scan_id=result["scan_id"],
            score=result["score"],
            context=context,
            site_id=site_id,
            batch_id=batch_id,
            flagged_region=result.get("flagged_region"),
        )
    return result

Deploy scan_sterile_ff_image before each fill-finish inspection AI classification call. On AdversarialSterileFFImageError for AVI_PARTICULATE: immediately hold the batch at the AVI station; notify the QC manager; require 100% re-inspection of the affected batch by trained operator visual inspection under 21 CFR Part 211.167(a)-compliant lighting conditions before any vials are transferred downstream. On AdversarialSterileFFImageError for CCI_DYE_INGRESS: hold the entire fill batch from the affected CCI test set; require independent re-test of 100% of vials by vacuum dye ingress method with trained operator image evaluation (not AI classification) before batch release. See also: pharmaceutical biologics cold chain temperature AI prompt injection (related biologic drug product AI adversarial surfaces) and free scanner — 10 scans/day, no card required. Get early access

Related questions